260 related articles for article (PubMed ID: 22455493)
1. Identifying targets in the hunt for effective respiratory syncytial virus interventions.
Tayyari F; Hegele RG
Expert Rev Respir Med; 2012 Apr; 6(2):215-22. PubMed ID: 22455493
[TBL] [Abstract][Full Text] [Related]
2. Respiratory syncytial virus disease mechanisms implicated by human, animal model, and in vitro data facilitate vaccine strategies and new therapeutics.
Moore ML; Peebles RS
Pharmacol Ther; 2006 Nov; 112(2):405-24. PubMed ID: 16820210
[TBL] [Abstract][Full Text] [Related]
3. New strategies for control of respiratory syncytial virus infection.
Nokes JD; Cane PA
Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
[TBL] [Abstract][Full Text] [Related]
4. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.
Elliott MB; Chen T; Terio NB; Chong SY; Abdullah R; Luckay A; Egan MA; Boutilier LA; Melville K; Lerch RA; Long D; Eldridge JH; Parks CL; Udem SA; Hancock GE
Vaccine; 2007 Oct; 25(41):7132-44. PubMed ID: 17850933
[TBL] [Abstract][Full Text] [Related]
5. Respiratory syncytial virus: reverse genetics and vaccine strategies.
Collins PL; Murphy BR
Virology; 2002 May; 296(2):204-11. PubMed ID: 12069519
[No Abstract] [Full Text] [Related]
6. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice.
Fu Y; He J; Zheng X; Wu Q; Zhang M; Wang X; Wang Y; Xie C; Tang Q; Wei W; Wang M; Song J; Qu J; Zhang Y; Wang X; Hong T
Biochem Biophys Res Commun; 2009 Apr; 381(4):528-32. PubMed ID: 19233131
[TBL] [Abstract][Full Text] [Related]
7. Translational sciences approach to RSV vaccine development.
Kurzweil V; Tang R; Galinski M; Wang K; Zuo F; Cherukuri A; Gasser RA; Malkin E; Sifakis F; Mendel DB; Esser MT
Expert Rev Vaccines; 2013 Sep; 12(9):1047-60. PubMed ID: 24053398
[TBL] [Abstract][Full Text] [Related]
8. A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age.
Langley JM; Sales V; McGeer A; Guasparini R; Predy G; Meekison W; Li M; Capellan J; Wang E
Vaccine; 2009 Sep; 27(42):5913-9. PubMed ID: 19651171
[TBL] [Abstract][Full Text] [Related]
9. Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation.
Stegmann T; Kamphuis T; Meijerhof T; Goud E; de Haan A; Wilschut J
Vaccine; 2010 Aug; 28(34):5543-50. PubMed ID: 20600502
[TBL] [Abstract][Full Text] [Related]
10. In search of a vaccine for respiratory syncytial virus: the saga continues.
Englund J
J Infect Dis; 2005 Apr; 191(7):1036-9. PubMed ID: 15747236
[No Abstract] [Full Text] [Related]
11. Chimeric subgroup A respiratory syncytial virus with the glycoproteins substituted by those of subgroup B and RSV without the M2-2 gene are attenuated in African green monkeys.
Cheng X; Zhou H; Tang RS; Munoz MG; Jin H
Virology; 2001 Apr; 283(1):59-68. PubMed ID: 11312662
[TBL] [Abstract][Full Text] [Related]
12. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.
Karron RA; Wright PF; Belshe RB; Thumar B; Casey R; Newman F; Polack FP; Randolph VB; Deatly A; Hackell J; Gruber W; Murphy BR; Collins PL
J Infect Dis; 2005 Apr; 191(7):1093-104. PubMed ID: 15747245
[TBL] [Abstract][Full Text] [Related]
13. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.
Cyr SL; Jones T; Stoica-Popescu I; Brewer A; Chabot S; Lussier M; Burt D; Ward BJ
Vaccine; 2007 Jul; 25(29):5378-89. PubMed ID: 17561317
[TBL] [Abstract][Full Text] [Related]
14. Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis.
Harcourt JL; Karron RA; Tripp RA
J Infect Dis; 2004 Dec; 190(11):1936-40. PubMed ID: 15529257
[TBL] [Abstract][Full Text] [Related]
15. Mucosal vaccines against respiratory syncytial virus.
Yang K; Varga SM
Curr Opin Virol; 2014 Jun; 6():78-84. PubMed ID: 24794644
[TBL] [Abstract][Full Text] [Related]
16. Respiratory syncytial virus infection and immunity.
González PA; Bueno SM; Carreño LJ; Riedel CA; Kalergis AM
Rev Med Virol; 2012 Jul; 22(4):230-44. PubMed ID: 22290692
[TBL] [Abstract][Full Text] [Related]
17. Advances in and the potential of vaccines for respiratory syncytial virus.
Jorquera PA; Oakley KE; Tripp RA
Expert Rev Respir Med; 2013 Aug; 7(4):411-27. PubMed ID: 23964629
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge.
de Waal L; Power UF; Yüksel S; van Amerongen G; Nguyen TN; Niesters HG; de Swart RL; Osterhaus AD
Vaccine; 2004 Feb; 22(8):915-22. PubMed ID: 15161068
[TBL] [Abstract][Full Text] [Related]
19. Antibody-dependent enhancement, a possible mechanism in augmented pulmonary disease of respiratory syncytial virus in the Bonnet monkey model.
Ponnuraj EM; Springer J; Hayward AR; Wilson H; Simoes EA
J Infect Dis; 2003 Apr; 187(8):1257-63. PubMed ID: 12696005
[TBL] [Abstract][Full Text] [Related]
20. Evolution of prophylaxis: MoAb, siRNA, vaccine, and small molecules.
Ramilo O
Paediatr Respir Rev; 2009 Jun; 10 Suppl 1():23-5. PubMed ID: 19651397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
